Experimental mRNA Delivery System Reactivates Hidden HIV in Laboratory Cells

A delivery breakthrough, not yet an HIV cure

Researchers in Melbourne have developed a lipid nanoparticle called LNP X that delivered messenger RNA into resting CD4 T cells with more than 75% efficiency in laboratory experiments. The system also reactivated dormant HIV in cells collected from people living with the virus, addressing a major obstacle in the search for a cure: reaching infected cells that remain silent during treatment.

The study, published on May 29, 2025, in Nature Communications, was conducted at the University of Melbourne's Peter Doherty Institute for Infection and Immunity. Researchers Paula Cevaal, Stanislav Kan, Bridget Fisher and Michael Moso worked in the laboratories of Sharon Lewin and Michael Roche.

The central finding concerns delivery and HIV reactivation, not the elimination of infection. Scientists used isolated cells, not a treatment administered to people. They did not demonstrate that LNP X cleared the HIV reservoir, allowed anyone to stop medication or produced a cure.

Lead study author Paula Cevaal, a researcher at the Doherty Institute, described the result in a statement:

As HIV cure researchers, our goal has been to reach the virus where it hides,

That distinction between reaching HIV and removing it matters. The experiment offers a way to make dormant virus active and potentially visible to immune defenses. A successful treatment would still need to ensure that infected cells are eliminated, or that HIV remains controlled without continuing antiretroviral medication.

Why suppressed HIV can return

Antiretroviral therapy stops HIV from multiplying and can keep the virus suppressed indefinitely. It helps people live longer, healthier lives and reduces the risk of transmission. Yet it does not remove every infected cell.

HIV inserts its genetic material into the DNA of human cells. Some infected CD4 T cells, which help coordinate immune responses, enter a resting state. The viral material can then remain largely inactive, producing too little viral activity to expose the infected cell to immune defenses.

These cells form part of the HIV reservoir. Some retain virus capable of restarting infection, which explains why HIV can rebound after treatment stops. Medication controls active viral replication, but dormant viral DNA presents a different problem.

The Melbourne research focuses on latency reversal: prompting hidden HIV to resume activity. This is sometimes called a "kick and kill" approach. The first step awakens the virus; the second must remove the infected cells. The new work advances the first step, while leaving the second unresolved.

What LNP X carries into resting cells

Messenger RNA, or mRNA, is a temporary set of instructions that a cell uses to make a protein. The researchers packaged those instructions inside lipid nanoparticles, tiny particles made from fatty materials that help transport their cargo into cells.

The broad delivery concept is familiar from mRNA vaccines against COVID-19. Here, however, the purpose was different: the researchers sought to deliver instructions into resting T cells and activate HIV already present inside them, rather than vaccinate someone against a new infection.

Resting CD4 T cells have been difficult to reach with mRNA. A delivery method must get enough material inside while avoiding damage or unwanted activation of the cells. LNP X was designed to address that problem.

The European AIDS Treatment Group's June 29 summary describes delivery of candidate tools including HIV Tat mRNA and HIV long terminal repeat CRISPR activation, known as CRISPRa. It identifies the findings as laboratory results, not evidence of an effective treatment in people.

The Tat experiments used mRNA encoding the first 72 amino acids of the HIV Tat protein. Tat helps activate viral transcription, the process by which genetic instructions are copied into RNA. Delivering instructions for this protein encouraged dormant HIV genetic material to become active.

What the experiments actually established

The reported delivery efficiency exceeded 75% in resting CD4 T cells. Transfection efficiency, the technical term for this measurement, describes how successfully genetic instructions are introduced into cells. It does not mean that 75% of HIV was removed or that 75% of infected cells were destroyed.

That distinction prevents a promising laboratory number from being mistaken for a cure rate. Efficient delivery is necessary for this approach, but it is only one part of the treatment scientists hope to develop.

The Tat mRNA reversed HIV latency in CD4 T cells taken from people with HIV and studied outside the body. These experiments are described as ex vivo, meaning the cells originated in people but were treated after collection.

Researchers reported no apparent toxicity and no unwanted T cell activation under the conditions tested. That is encouraging because some previous attempts to reverse latency have suffered from weak activity or harmful effects beyond their intended target.

Laboratory observations do not establish safety throughout a living body. Cells in a dish receive a controlled exposure; particles administered to a person must circulate, reach relevant tissues and deliver their cargo without causing unacceptable effects elsewhere. The study did not resolve those challenges.

CRISPR delivery is a separate result

LNP X also delivered tools for CRISPR activation. CRISPRa uses components derived from CRISPR technology to increase activity at a selected genetic target. It is different from using CRISPR to cut out HIV DNA or permanently disable it.

The detailed account of these experiments places the CRISPR activation demonstration in an immortalized human T cell line, a population of cells maintained for repeated laboratory study. The Tat latency reversal experiments, by contrast, included CD4 cells collected from people with HIV.

Broader descriptions group Tat and CRISPRa together as candidate tools carried by LNP X. The distinction between their experimental settings is important: a result in a laboratory cell line does not establish the same performance in resting cells from patients, much less in a person.

Researchers demonstrated a delivery platform with more than one possible cargo. They did not show that this platform excised HIV from human cells in a clinical setting. Genetic removal or permanent inactivation of HIV remains a possible future application, not an outcome established by this study.

Reactivation still needs a way to clear infected cells

Making HIV active may reveal an infected cell through the viral material it produces. That can create an opportunity for immune defenses or another treatment to remove it. Exposure alone, however, does not guarantee that the cell will be killed.

Earlier latency reversal agents increased HIV activity in laboratory experiments but did not, on their own, reliably reduce the reservoir. Some also acted beyond HIV and could cause toxicity. Those experiences explain why a stronger reactivation method still needs to be tested as part of a complete treatment strategy.

The Melbourne team is investigating a way to deliver instructions without broadly activating T cells. Reactivating the virus and activating the entire immune cell are different biological events. Avoiding the latter may help limit unwanted effects, although that advantage still requires testing beyond isolated cells.

A future approach would likely combine latency reversal with another intervention that helps remove infected cells, such as a treatment that strengthens an immune response against HIV. The research has not established which combination would work, how much reservoir reduction it could achieve or whether it would prevent viral rebound.

From a 2020 idea to animal testing

Sharon Lewin, who oversaw the research with Michael Roche, traced the program to work that began during the COVID-19 pandemic. In a statement, she explained how an earlier mRNA project prompted the HIV research:

Back in 2020, my lab started looking at mRNA to deliver a new treatment for COVID-19. That work sparked a lot of new ideas for HIV, despite the two being very different viruses,

The sequence shows both the years of development behind the finding and how early the proposed treatment remains:

• 2020: Lewin's laboratory began exploring mRNA delivery for a potential COVID-19 treatment, work that helped inspire the HIV program.
• May 29, 2025: Nature Communications published the LNP X study.
• June 2025: Accounts of the findings described preparations for preclinical animal testing.
• June 29, 2025: The European AIDS Treatment Group published its summary of the laboratory results.

No date for the start of human trials was given. Animal testing must first examine whether delivery and HIV reactivation can work safely in a living organism.

What must be tested before people can benefit

Further studies need to establish the appropriate dose, safety and biodistribution. Biodistribution means where the nanoparticles travel and accumulate in the body. A system that reaches isolated cells efficiently may behave differently when exposed to organs, tissues and other cell types.

Researchers also need to determine whether enough of the relevant reservoir can be reached and whether reactivation can be paired with reliable clearance. A clinical program would have to distinguish a temporary increase in HIV activity from a lasting reduction in infection.

Physician Benjamin Young, M.D., Ph.D., estimated an optimistic development sequence of two to three years of studies outside humans, followed by potentially up to 10 years of human trials across phases 1, 2 and 3. Those phases generally move from initial safety testing toward assessing effectiveness and confirming results in larger groups.

That estimate is not a timetable announced by the researchers, and progress depends on each stage producing acceptable results. It means a clinically useful treatment could take many years to establish, even if development succeeds.

The delivery platform may also have uses beyond HIV. Michael Roche, who jointly oversaw the work, identified cancers and autoimmune conditions as possible areas for future investigation:

The white blood cells where HIV hides are also involved in other diseases, including some cancers and autoimmune conditions,

Those possibilities rest on the ability to carry different instructions into relevant immune cells. The HIV experiments do not establish effectiveness against cancer or autoimmune disease. For people living with HIV today, the practical message is unchanged: these laboratory findings are not a reason to stop antiretroviral therapy.

Key Points

• The May 29, 2025, study tested LNP X in laboratory cells, not as a treatment administered to people.
• Reported mRNA delivery efficiency exceeded 75% in resting CD4 T cells. This was not a cure rate.
• Tat mRNA reactivated dormant HIV in cells collected from people living with the virus.
• No apparent toxicity or unwanted T cell activation was observed under the laboratory conditions tested.
• CRISPR activation delivery was also demonstrated, with the detailed account identifying an immortalized T cell line.
• Animal studies, dose assessment and safety testing are needed before human trials. No trial start date was announced.
• Reactivating HIV does not by itself clear infection. Antiretroviral treatment remains necessary.